Dan. Thanks
Avid's yielded During project the and our both great in increased aggressive as to fourth industry expand pipeline work our dividend. client quarter, visibility as our well base,
of and had presence at several Interfax. events industry's conferences, DCAT a we not quarter, attended the strong and During but the including to, best Week limited
were was commenced the focused International an XXXX for end, the preparation our quarter we coming As on heavily quarter end. which subsequent to BIO to Convention,
as Women sponsoring of industry, and the current and build potential brand customers with such and awareness and key also supporting conference therapeutics In organizations, while our Part was Bio. DCAT and industry further meeting bio messaging new in this to
our of continues log to of outreach result as business continuous well grow. a new As as exposure, this discussions our efforts, customer
and influx are high potential new customers proposals, for the and gaining by evidenced number industry of key important meetings subsequent of for request conferences and traction As we with partners.
existing Equally continue business new important, customers. to win with today's financial we demonstrated, results the we have as believe is the
new, business these of results are manufacture completely some While expansion of of from many a or of current development new molecules. requiring project, and these projects the
These incredibly wins for are reasons. several valuable
as the assurance through the more follow-on First, program represent and stage molecules various the need earlier for maybe existing validation phase, both commercial manufacturing. as production regulatory leading opportunities stages. advances phase certainty and providing for commercial stage, with from long-term as of customers projects to later early well Other
Second, for as on-boarding making process aspects and much the have more profitable with efficient projects already companies, of working more less Avid. a other and these are costly, we relationship these
fact relationships testimonial established expertise our repeat and our And our quality and most our Avid. projects nature processes the for importantly, that come the multiple The many team, we from clients, finally, of the of is of great back of speaks facilities to clients state-of-the-art our the product. collaborative the business have with a
our I enzyme, Halozyme's development. not hyaluronidase Avid would one customers. candidates now Halozyme but for like of continues product collaboration collaboration product to ENHANZE largest human Therapeutics manufacture in for to technology manufactures to currently increase demand provide also an product, with update only recombinant respect currently the supporting for of platform. their
whom depleting strengthened believe due We Halozyme their is a partner to partially Avid are for key that the exclusive supplier the inventories. forecasts
Halozyme's as partners, their partners their We well this continue program begin is development demand this trend preparing projects new market and product by that new Halozyme's growth driven commercial More development by importantly, fiscal commercialization. launches clinical and into as for also products. year XXXX anticipate will advance for as
discussed Halozyme we of of process in on commercial recently anticipation manufacturing new a last Avid As campaign for process behalf validation completed quarter, scaled up future a manufacturing.
for completed recently of completed, second associated global process key validation validation regulatory progress. represents that have of with XXXX we is fiscal process specification another in a addition, In the the part Once campaign campaign process filings. a
process. required becomes facility part The in process consumers specified manufacture and the the the to approval product specified manufacturing of using
the end no take clinical course a the process. of reviews years, Of there's guarantee trials and of at and approval drug regulatory
for at However, manufacturing those at approved be processes Avid. validated commercial will conducted Avid is the that using products likely
the to expensive To new risky, process with re-filing point are move another regulatory validation time consuming require a business and agency, which propositions. that the highly would and CDMO at
see great For we build completed opportunity these business as the commercial validation reasons, in future. to a each today process
our remain to regulatory in general. about approval biopharmaceutical products clients uniquely positioned very who serve time community, are in demand believe line. the we excited developing And the We history, with we are accelerated with
disease us partners. rare allows strategy the to support Importantly, development product
size configuration our with of ensure of As support regardless into flexibility to our the the to is and mindset of combined this patient all goal. our the medicines design, aim is a for CDMO, built foster of clients The facility to continues availability population. leadership our
development our members year, essential met project the approach. customer management standards and centric business our set team the high to During and
we are fiscal in excited growth forward, increasing expanding Looking fuel and expect continued new utilization to opportunities and capacity that XXXX. by the we
And my concludes to This call business back now Rick. I'll hand Rick? overview. the
